{"id":50721,"date":"2025-12-14T21:03:36","date_gmt":"2025-12-14T13:03:36","guid":{"rendered":"https:\/\/flcube.com\/?p=50721"},"modified":"2025-12-14T21:03:37","modified_gmt":"2025-12-14T13:03:37","slug":"joincares-pixavir-marboxil-wins-nmpa-approval-as-first-single-dose-flu-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50721","title":{"rendered":"Joincare\u2019s Pixavir Marboxil Wins NMPA Approval as First Single\u2011Dose Flu Treatment"},"content":{"rendered":"\n

Joincare Pharmaceutical Group Industry Co., Ltd.<\/strong> (SHA: 600380<\/a>) announced that its Class\u202f1 innovative drug<\/strong>, Pixavir Marboxil Capsules<\/strong>, received marketing approval from China\u2019s National Medical Products Administration (NMPA)<\/strong>. The drug is the first domestically developed cap\u2011dependent endonuclease inhibitor<\/strong> offering a single oral dose<\/strong> to complete the entire treatment course for influenza A and B in patients aged 12 and older<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Approval Date<\/strong><\/td>11\u202fDec\u202f2025<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Product<\/strong><\/td>Pixavir Marboxil Capsules (oral)<\/td><\/tr>
Drug Class<\/strong><\/td>Class\u202f1 innovative drug (cap\u2011dependent endonuclease inhibitor)<\/td><\/tr>
Indication<\/strong><\/td>Influenza A or B in adolescents (\u226512) and adults<\/td><\/tr>
Innovation<\/strong><\/td>First domestic single\u2011dose oral regimen<\/strong> for influenza<\/td><\/tr>
Launch Timeline<\/strong><\/td>Q1\u202f2026 (hospital and retail channels)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Clinical Advantages<\/h2>\n\n\n\n
Attribute<\/th>Pixavir Marboxil<\/th>Competitive Landscape<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Cap\u2011dependent endonuclease inhibitor<\/td>Novel vs. neuraminidase inhibitors (Tamiflu)<\/td><\/tr>
Dosing<\/strong><\/td>Single oral dose<\/strong> (complete course)<\/td>Tamiflu requires 5\u2011day BID regimen<\/td><\/tr>
Cross\u2011Strain Coverage<\/strong><\/td>Effective against both Influenza A and B<\/strong><\/td>Broad-spectrum activity<\/td><\/tr>
Onset of Action<\/strong><\/td>Rapid symptom relief<\/strong> (shortens duration)<\/td>Faster than standard of care<\/td><\/tr>
Safety Profile<\/strong><\/td>Favorable across all populations<\/td>Improved tolerability vs. existing agents<\/td><\/tr>
Convenience<\/strong><\/td>Ideal for peak flu season<\/strong> and family emergency reserves<\/strong><\/td>Addresses compliance gaps<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Implication<\/th><\/tr><\/thead>
China Influenza Cases<\/strong><\/td>~\u202f15\u201120\u202fmillion treated annually (2024)<\/td>High seasonal demand; <30% receive antivirals<\/td><\/tr>
China Antiviral Market<\/strong><\/td>\u00a54.5\u202fbillion (\u2248\u202fUS$630\u202fM)<\/td>Dominated by Tamiflu (Roche) generics<\/td><\/tr>
Pixavir Peak Sales<\/strong><\/td>\u00a52.5\u20113.5\u202fbillion<\/strong> (\u2248\u202fUS$350\u2011490\u202fM) by 2030<\/td>30\u201140% share of branded antiviral segment<\/td><\/tr>
Pricing Strategy<\/strong><\/td>Premium pricing justified by single\u2011dose convenience<\/td>NRDL negotiation planned for 2026<\/td><\/tr>
Competitive Moat<\/strong><\/td>First\u2011in\u2011class mechanism<\/strong> and compliance advantage<\/strong><\/td>3\u2011year market exclusivity as Class\u202f1 innovation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n